Lv11
20 积分 2024-06-14 加入
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation
1小时前
待确认
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
22天前
已完结
Antibody Library Screening Using Yeast Biopanning and Fluorescence-Activated Cell Sorting
1个月前
已完结
Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity
1个月前
已完结
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
1个月前
已完结
One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn’s-like inflammatory bowel disease
1个月前
已完结
Opportunities and limitations of B cell depletion approaches in SLE
1个月前
已完结
In vivo CAR T cell generation to treat cancer and autoimmune disease
1个月前
已完结
Opportunities and limitations of B cell depletion approaches in SLE
2个月前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
2个月前
已完结
皖公网安备34019202002308
